CTIX News 11/11/2014 16:27:14 $CTIX Good closing volume

New Post Public Reply Private Reply Replies (0) Message Board
Jake13
CTIX News 11/11/2014 16:27:14 $CTIX
Good closing volume with a block buy at 50k shares at 3:59. Again, that one trade is ~165k which is generally beyond most retailers. I think given the potential upside catalysts we'll see a continuation of today's run with bigger volume.

I think the news of today's PR is just getting out. One guy I talked to started a 100k personal position and will add professionally when able.

The future looks great both short and long term.
Can someone remind me why we are going into Phase II for B-OM and not Phase I....I know I should know this but for some reason it completely escapes me....although I am very happy about it, I cannot for the life of me remember why.
I can only imagine what you pocketed on this little unexpected CTIX PR run....

Stay stateside and throw that party, actually oysters are better during the winter harvest, so we fellow shareholders can wait till after that San Fran trip.
Not worth it IMHO. Stay cavalier, do a B deal to kick off with a top 5, and don't panic, all is good in the ctix hood. Science will trump all and create the value not impatience.
Yea the "aww shucks" was getting real old,.

GLTA CTIXers
Over the next six weeks we have:
Start of the B-OM trial at MD Anderson
Start of K in AML at UofB
Bottom line B 2b results with FDA comments which could be huge!!
Prurisol FDA meeting
And just because of the last PR perhaps even more information on Kevetrin solid tumors p1????
Uplisting???

Anything else? Not sure what the share price will be but the entertainment value is going off the charts for me.

For the Bakers, private placement sell of 10-20 million shares at current market prices of course and a seat on the board.
I did at $3.32. With reservations of course.

Close at the high is worrisome but volume wasn't striking. Suspect next big push related to B results.

Won't wait long to reload if funds available.
Baker Bros! I would think we are on the verge of one of these entities endorsing CTIX.
I imagine you saw what I saw today. Demand at the upper ranges of today's trade range ($3.30+). Smart money? Not sure myself. But, could be some fresh money is coming into play.

Looking at the trade, I think it likely that the PPS goes back to test recent highs. There should be (natural) resistance at this level. Still 5%+ to go before.

Not sure if most have observed what I have. Weakness has been more a product of weak demand (buying), not over supply (selling). This phenomena (weak demand) was one of the clues I used in determining that CTIX was ready for some consolidation, last week. Probably not a coincidence that CTIX was in overbought territory, that it had tested the high range and failed several times, and that volume was getting lighter (just before the minor correction/consolidation).

Volume means different things at different times. For instance, the drying up of volume at the end of a consolidation is a good thing (sellers are near finished). But, volume drying up at the end of a strong move higher is most likely bad news, as demand is slacking off. Big increases in volume (40% plus) can signal turnarounds. Just as candlesticks need to be interpreted in the context of dynamic trading, so too volume.

Liked the volume today. Like that stochastics are low. Like that CTIX is trading within Bollinger bands. Waiting to see how CTIX reacts when hitting resistance and in overbought territory. It's coming. Not today. The market will tell. Then, breakout or consolidation. Consolidation or correction.

Hope you noticed that during the long run from $1.60, I was not taken in by many of the short-term, head fake consolidations.

One also needs to put recent PPS activities in context. CTIX has a much higher market value than just a few months ago). Compared with today, trading a few months ago was much less risky (in price terms). Also, CTIX has been advancing its technologies, which has reduced risk. Then there is the shelf offering, and new COO (with compensations). Pluses and minuses, and will depend on one's perspective. My perspective, it's more positive.

Happy trails, I mean trading:


remember when jb and greyhound went to the feb conference? jb quoted dr menon as saying (in regards to p53 & p21) that dana farber wanted to see the graphs (dosage & expression) go up at the same time.

from todays pr

preliminary data show that 50 percent of patients treated with kevetrin hrough the eighth cohort demonstrated enhancement in p21 expression in peripheral blood cells and that these observations appeared dose related

......Initial comparisons between early and latter cohorts
support cellceutix's expectation that p53 is dependent on exposure to kevetrin.

in other words the amount of increase of p21 is dependent on the amount of kevetrin injected. the graphs correlate.

now the last thing we need to hear is how this affects the tumors.

You may be thinking of Baker Bros.
Sabby and 3 or 4 others are also really big in biotech/pharmas.
volume is AWESOME today! close at EOD high!
Weekly is almost bullish engulfing!
Nice move today for CTIX...


was 900k shares good volume for this day?

Now it needs to hold support above the 3.00-3.15 area to stay looking good. (technically speaking of course...)
Even a well known science/medical magazine feature would be a nice start. I forget who the group is that is real influential in biotech investments, but surprised we haven't seen them enter the picture. Maybe they are accumulating currently.

Yep, don't want to be out when something like this hits, and an RSI of 95 won't stop a huge gain from that type of exposure.
HOLY SHITOWSKI and I ain't POLISH !

I LOVE LEO & the CTIX LEADERSHIP GANG !

GOOOOOOOOOOOOOOOOO CTIX !
We should start a pool for which network will pick up the CTIX story first...
Yes today was awesome!
You know, today really was enjoyable. And I'm tempted to make a special trip just to see the display at the tower of London...that may well be the best signature you've ever posted.
Securities Registration Statement (simplified Form) (s-3/a) "Edgar (US Regulatory)" - 11/10/2014 5:31:51 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/10/2014 4:16:35 PM
Hot Stocks to Follow for Investment Opportunity & Special Profile "InvestorsHub NewsWire" - 11/6/2014 6:00:00 AM
Securities Registration Statement (simplified Form) (s-3) "Edgar (US Regulatory)" - 10/30/2014 4:31:15 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/24/2014 6:04:28 AM
ALTITRADE PARTNERS™ SAYS A KEY-REVERSAL DAY COULD HAPPEN THIS WEEK "InvestorsHub NewsWire" - 10/14/2014 6:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/24/2014 3:48:22 PM
Annual Report (10-k) "Edgar (US Regulatory)" - 9/15/2014 1:50:04 PM
Statement of Ownership (sc 13g) "Edgar (US Regulatory)" - 9/4/2014 4:14:23 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/2/2014 6:29:26 AM
Cellceutix Anti-Fungal Compounds Awarded $1.5 Million SBIR Grant "Marketwired" - 6/23/2014 7:00:00 AM
Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin Entering Eighth Cohort "Marketwired" - 6/16/2014 7:00:00 AM
Cellceutix Completes Patient Enrollment in Clinical Trial of Prurisol "Marketwired" - 6/2/2014 7:00:00 AM
Cellceutix Signs Material Transfer Agreements for Defensin Mimetic Compounds With Leading Universities "Marketwired" - 5/27/2014 7:00:00 AM
Cellceutix Plans for Entry in Diabetic Foot Wound and Ulcer Market "Marketwired" - 5/19/2014 7:00:00 AM
Amended Quarterly Report (10-q/a) "Edgar (US Regulatory)" - 5/16/2014 11:57:54 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 5/12/2014 10:12:29 AM
Cellceutix Confident in Its Formidable Antibiotic Arsenal "Marketwired" - 5/12/2014 7:00:00 AM
Cohort Completed in Cellceutix Clinical Trial of Prurisol for Psoriasis "Marketwired" - 5/5/2014 9:53:20 AM
Study Shows Cellceutix Antibiotic Active Against Drug-Resistant Superbug Klebsiella Pneumoniae "Marketwired" - 4/14/2014 6:30:00 AM
Cellceutix Comments on Positive FDA Advisory Vote for Dalbavancin and Tedizolid "Marketwired" - 4/1/2014 8:00:00 AM
Cellceutix Reports 20 Percent Enrollment Completed in Phase 2b Trial of Brilacidin as Short-Course Therapy for ABSSSI "Marketwired" - 3/31/2014 9:25:00 AM
Cellceutix Initiates Clinical Trial of Prurisol as New Treatment for Psoriasis "Marketwired" - 3/25/2014 6:00:00 AM
Cellceutix to Initiate Psoriasis Clinical Trial "Marketwired" - 3/21/2014 6:00:00 AM
Seventh Cohort Underway in Cellceutix Clinical Trial of Kevetrin for Solid Tumors "Marketwired" - 3/19/2014 8:40:37 AM
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Curaleaf Eyes Growth: Conference Signals Opportunities

Updated Category News Views 1

Curaleaf's Strategic Move: Getting in Front of Investors Here comes Curaleaf Holdings, stepping into the spotlight with their eye on increasing investor engagement. Announcing their participation in the ATB Cormark Capital Markets 2026 Fall Institutional Investor Conference, the folks at Curaleaf aren't just talking—they're putting their top brass under the lights. You...

Continue Reading
Hydrogen Mobility Gains Steam: Industry & Policy Unite

Updated Category News Views 2

The winds are changing, and this time, it's hydrogen that's blowing into town. Europe may just be on the brink of a major trucking overhaul, driven by a concoction of industry giants and supportive policies. The stage is set for hydrogen trucks to roll out by 2030, aiming to gut traditional fuel options and stack the odds in favor of zero-emission transport. Can you smell...

Continue Reading
Russo-Rodriguez: A New Era in Florida Politics?

Updated Category News Views 3

A Political Shake-Up in Florida On a seemingly regular day in New Smyrna Beach, Frank Russo, the independent candidate for governor, decided to toss a wrench into Florida's political machine. By naming Rachel Rodriguez as his running mate, he's forging a new path that challenges entrenched party norms. This Russo-Rodriguez ticket is stirring the political pot,...

Continue Reading
PROCEPT Faces Legal Storm Over Sales Practices Missteps

Updated Category News Views 1

Investors Take Aim: A Legal Showdown on the Horizon There's a brewing storm over at PROCEPT BioRobotics—ticker NASDAQ:PRCT if you're tracking. These folks are knee-deep in a securities class action lawsuit from investors who’ve taken a financial wallop. The lawsuits are triggered by allegations of shady sales techniques that artificially bumped up their unit sales...

Continue Reading
Allison Ng Earns Prestigious NAPABA 'Best Under 40' Award

Updated Category News Views 0

Allison Ng's Achievement: Beyond the Legal Grind Without warning, the legal world has another star rising up through its ranks, and this time it's Allison Ng catching the spotlight. She’s tucked away in Greenberg Traurig’s Atlanta office, plugging away in pharmaceutical and medical device litigation. But every now and then, these legal eagles get a chance to spread...

Continue Reading
Connected Retail Security: Rising Risks and Fragmented Roles

Updated Category News Views 0

Cyber Threats in the Connected Retail Landscape The retail world isn't what it used to be. Walk into a store today, and you're greeted not just by products but a web of interconnected systems screaming for attention. Sure, you've got your old-school POS systems humming along, but they're just one brittle cog in a rattling machine of IoT devices, cloud platforms, and...

Continue Reading
EzCheckPrinting Boosts Remote Check Solutions Cost-Effectively

Updated Category News Views 2

Navigating the Check Printing Landscape Let's dive right into the changing realities of the workspace. With remote work becoming the new standard, small businesses are juggling tighter budgets while trying to maintain smooth financial operations. It's a hard game, but here is where Halfpricesoft.com rolls out their newly upgraded multi-user ezCheckPrinting software,...

Continue Reading
Smithfield's Foreign Lobbying Interests Unveiled Amid Uproar

Updated Category News Views 1

A Behind-the-Scenes Drama Over Lobbying Disclosure Something's fishy beneath the surface of Smithfield Foods' recent lobbying debacle. The Center for Responsible Food Business (CRFB) has turned the spotlight on some shady practices, and folks, it ain't pretty. Smithfield's lobbyists had been ducking disclosure rules apparently meant to keep track of foreign influence. Who...

Continue Reading
Aurra Markets Wins 'Most Transparent Broker' Award 2026

Updated Category News Views 2

Spotlight on Transparency in Trading Alright, so Aurra Markets snagged the 'Most Transparent Broker' award at the Money Expo in Mumbai this year. From the greasy streets of trading floors to the polished halls of Jio World Convention Centre, transparency is one of those golden words you hear tossed around, but like finding a needle in a haystack, it’s not always easy to...

Continue Reading
Cango's EcoHash Marks AI Move with Key Milestones

Updated Category News Views 4

AI Expansion at EcoHash: A Strategic Stride Some days you wake up, read a company pushing its legacy into something new, and you just gotta wonder if they’ve hit paydirt or just blowing smoke. For Cango Inc. and its subsidiary EcoHash, this latest update is shaping up interesting. They're no small potatoes in mining Bitcoins, but they're now trying their hand at AI...

Continue Reading

Top 5 Most Recently Viewed Articles

Grand Gallery Inc. Addresses Domain Misuse Concerns

Updated Category News Views 181

Grand Gallery Inc. Addresses Domain Usage Issues Grand Gallery Inc. (OTC:COSG) has recently issued a statement regarding troubling matters related to the ownership and usage of the domain www.coinllectibles.art. The Company, previously known as Cosmos Holdings Inc., had once owned this domain before a significant rebranding effort. As part of its strategic transition,...

Continue Reading
Orbee Secures Funding to Propel Automotive Industry Growth

Updated Category News Views 183

Orbee Secures Strategic Financing for Market Expansion Orbee, Inc., a notable provider of data management and middleware software tailored for the automotive industry, is taking significant strides to enhance its market position. The company recently announced the acquisition of additional capital investments to elevate its sales and customer support efforts while...

Continue Reading
Euro Manganese Welcomes New Director to Enhance Leadership Team

Updated Category News Views 109

Euro Manganese Inc. took a bold step back in 2024 when it brought on board Ms. Ludivine Wouters as a non-executive Director. This move was no ordinary appointment; it marked a significant shift in the company’s strategy as it aimed to solidify its presence in the battery materials sector, especially crucial for the electric vehicle (EV) industry. Strategic Shift: New...

Continue Reading
Monoclonal Antibody Market Insights: Growth and Innovations Ahead

Updated Category News Views 118

Trends in the Monoclonal Antibody Market for Asthma and COPD The evolving landscape of the monoclonal antibody for asthma and COPD market is set to witness remarkable growth, projected to expand from USD 35.94 billion in 2026 to an impressive USD 58.94 billion by 2035. This growth encompasses a compound annual growth rate (CAGR) of 5.65%, driven by an increasing...

Continue Reading
Vantage Shines as Most Trusted Broker with Social Impact Awards

Updated Category News Views 167

Vantage's Prestigious Awards Recognize Trust and Social Commitment In a remarkable achievement, Vantage Markets has recently been awarded the titles of "Most Trusted Broker" and "Best Corporate Social Responsibility" at the Professional Traders Awards 2024. This recognition underscores the broker's steadfast commitment to building trustworthy relationships with its...

Continue Reading